1. Scrip
  2. >>Focus On Asia

Oscotec's SYK Inhibitor Program Gets Korea Drug Fund Money

 
• By Jung Won Shin

Oscotec is set to accelerate the development of a novel oral rheumatoid arthritis drug, helped by financial support from the state-run Korea Drug Development Fund for a US Phase I clinical trial of the South Korean venture’s spleen tyrosine kinase inhibitor.

SEOUL – The state-run Korea Drug Development Fund (KDDF) has selected the Phase I clinical trial of Oscotec Inc.'s novel oral rheumatoid arthritis drug candidate SKI-O-703 as a project eligible to receive its financial support. SKI-O-703 selectively inhibits spleen tyrosine kinase (SYK), an enzyme linked to various inflammatory diseases including rheumatoid arthritis.

During a preclinical study completed in the US in 2014, SKI-O-703 showed a good toxicity profile and excellent safety margin...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.